Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epacadostat + Idarubicin + Cytarabine in First-line AML
NCT03444649Phase 1Withdrawn
- Sponsor
- Insel Gruppe
- Start
- Sep 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of epacadostat in acute myeloid leukemia (AML), sponsored by Insel Gruppe. Primary endpoints: Maximum Tolerated Dose at 30 days and Dose-Limiting Toxicities at 30 days. Planned start Sep 2018; status: withdrawn.
02
Drugs
epacadostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03444649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03444649.